Included In This Lesson
Outline
What is the Generic Name
AXITINIB
What is the Trade Name for AXITINIB
INLYTA
What is the Indication for AXITINIB
- 1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
View Our Nursing Pharmacology Course
References: https://open.fda.gov/
Other Pharm Resources